• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Rwandan Cohort Study Identifies Exploratory Genetic Locus Linked to HPV Persistence

by
November 17, 2026
in Cancer
Reading Time: 7 mins read
0
Rwandan Cohort Study Identifies Exploratory Genetic Locus Linked to HPV Persistence

Rwandan Cohort Study Identifies Exploratory Genetic Locus Linked to HPV Persistence

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In an exploratory genome-wide association study conducted in East Africa, medical researchers investigating host genetic factors in human papillomavirus infection have identified a candidate genetic variant linked to viral persistence among women living with HIV in Rwanda. The primary cluster-stratified Cochran–Mantel–Haenszel analysis revealed that a single nucleotide polymorphism designated rs13158830, located within the first intron of the PPARGC1B gene on chromosome 5, surpassed the conventional threshold for genome-wide statistical significance when comparing individuals with persistent infections to those who successfully cleared the virus. However, because this statistical signal was driven by an alternative allele observed in only four participants out of twenty-four persistent cases and absent in all one hundred and ten individuals who cleared the infection, the investigators emphasized that the finding is accompanied by substantial statistical uncertainty. The investigation represents the first genome-wide association study directly comparing individuals who cleared genital human papillomavirus against those who exhibited persistent infection within a cohort of women living with HIV on the African continent.

Persistent infection with high-risk human papillomavirus is recognized as the primary causative factor in the pathogenesis of cervical cancer, which remains the leading cause of cancer-related mortality among women in sub-Saharan Africa. Even within the contemporary therapeutic context of effective antiretroviral therapy, women living with HIV face a sixfold higher risk of developing cervical malignancy compared to their HIV-negative peers, and adolescent girls living with HIV exhibit diminished immunological responses following standard prophylactic vaccination. Although prior genomic investigations have firmly established that variations within human leukocyte antigen genes modulate the long-term risk of invasive cervical neoplasia, very few studies have probed the earlier stages of the disease continuum to elucidate why certain individuals fail to clear high-risk viral strains. Previous host genetic susceptibility research across Africa had been limited to two genome-wide association studies conducted in Nigeria, neither of which contrasted participants who cleared their infections against those experiencing long-term viral persistence.

Clinical screening coverage remains a persistent challenge throughout East Africa, where screening is primarily directed toward populations categorized as high risk. Prior survey data from the HIV clinic at the University Teaching Hospital of Kigali in Rwanda demonstrated that only fifty-five percent of attending women living with HIV had previously received a Pap smear, while corresponding screening rates reached only twenty-eight percent among women attending the HIV clinic at Black Lion Hospital in Addis Ababa, Ethiopia. To investigate host factors influencing viral trajectories, researchers recruited four hundred and sixty-three women living with HIV who were receiving antiretroviral therapy at the University Teaching Hospital of Kigali in 2021. Eligible participants were at least twenty-one years of age, possessed confirmed HIV diagnoses, and were voluntarily seeking cervical screening. Women were excluded if they had received prior vaccination against the virus, had present or historical diagnoses of cervical lesions or cancer, exhibited other visible or known vaginal or cervical infections, reported no sexual activity with others, or presented conditions impeding study compliance.

At the study baseline, enrolled participants completed comprehensive behavioral interviews before clinical physicians obtained cervical and vaginal swab samples utilizing the Aptima Multitest Swab system for viral genotyping, alongside supplementary swabs collected in RIPA buffer for molecular biomarker assessments. Peripheral venous blood samples were systematically collected into EDTA tubes, stored at minus seventy degrees Celsius, and subsequently processed through automated magnetic nucleic acid isolation to yield purified genomic DNA for micro-array genotyping. Cervical cytological specimens were acquired using a combination of wooden spatulas and cyto-brushes for evaluation under the 2014 Bethesda reporting system. Following an interval of approximately two years, three hundred and eighty-five participants returned for re-interview and identical clinical sampling procedures in 2023, enabling the research team to evaluate longitudinal changes in viral presence across both anatomical compartments.

Laboratory detection of viral DNA was executed using real-time quantitative polymerase chain reaction assays designed to detect twelve high-risk types, including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, alongside two low-risk strains, types 6 and 11, and human beta-globin as an internal housekeeping reference. Study participants were classified as ever infected if viral DNA was amplified at baseline, follow-up, or both visits, whereas those testing negative across both evaluations were defined as never infected. For persistence evaluations, women who tested positive at baseline and subsequently tested negative for all baseline types at the two-year visit were classified as cleared. Conversely, participants retaining identical viral genotypes across the two-year interval were operationally classified as exhibiting persistent infection, categorized as fully persistent if all baseline genotypes remained detectable or partially persistent if only a subset was retained. The authors cautioned that because testing occurred at only two discrete time points two years apart, same-type redetection could not definitively distinguish uninterrupted continuous viral persistence from viral clearance followed by same-type reinfection or intermittent molecular detectability.

Epidemiological profiling of the cohort revealed that among women testing positive for human papillomavirus at baseline, 38.6 percent harbored multiple concurrent genotypes, with type 52 representing the most frequent strain in multiple infections at 35.4 percent, followed by type 58 at 30.8 percent, type 56 at 27.7 percent, and type 16 at 24.6 percent. Longitudinal follow-up indicated that half of the total cohort remained negative across both time points, while 28.8 percent achieved complete viral clearance, 8.1 percent demonstrated partial clearance, and 6.8 percent acquired new infections between visits. Persistent infection occurred in 6.2 percent of the overall cohort, representing 33.1 percent of the one hundred and sixty-six women who were infected at baseline. Type-specific viral persistence reached 21.5 percent across four hundred and sixty-five evaluated infections. Persistent cervical infections were significantly more frequent for type 16 at 38.7 percent and type 18 at 33.3 percent compared to 16.0 percent for other high-risk genotypes, with similar elevations documented in vaginal swabs.

Genotyping was performed utilizing the Illumina Global Screening Array Multiple Disease platform, interrogating 730,059 single nucleotide polymorphisms across baseline blood DNA samples. The primary genome-wide scan evaluated three core phenotypic contrasts: ever infected versus never infected comprising 192 individuals against 193 controls; fully persistent infection versus complete clearance comprising 24 cases against 111 controls; and combined partially or fully persistent infection versus clearance comprising 55 cases against 111 controls. Population stratification and genomic calibration were monitored using principal component analyses and quantile-quantile distributions, which demonstrated excellent calibration across the 437,162 valid test markers in the persistence scan, reflected by a genomic inflation factor of 1.010. Exploratory gene-based aggregation testing was conducted using the Sequence Kernel Association Test framework restricted to rare and low-frequency variants captured on the array, while biological pathways were annotated through fixed two-hundred-kilobase physical proximity windows around the top five hundred markers.

The primary cluster-stratified Cochran–Mantel–Haenszel persistence scan identified the intronic variant rs13158830 on chromosome 5 as the sole marker exceeding genome-wide significance, recording an unadjusted p-value of 7.82 × 10⁻¹⁰. Genotypic inspection demonstrated that all one hundred and ten individuals who cleared infection were homozygous for the G allele, whereas among the twenty-four women with fully persistent infection, twenty were homozygous G/G, three were heterozygous A/G, and one was homozygous A/A. A two-sided Fisher exact test evaluating carrier status against non-carrier status maintained statistical significance with a p-value of 8.28 × 10⁻⁴. In sensitivity analyses employing Firth penalized logistic regression adjusted for the first four genetic principal components, the dosage association remained significant with an estimated beta of 4.09, yielding an odds ratio of 59.6 and a p-value of 9.18 × 10⁻⁵. However, the associated profile-likelihood 95 percent confidence interval spanned from 5.14 to approximately 8,380, directly reflecting sparse cell counts and precluding interpretation of the odds ratio as a precise effect size.

Beyond the lead locus, twenty-six of the top thirty single nucleotide polymorphisms associated with viral persistence exhibited minor allele frequencies below five percent, and twenty were completely absent among individuals who successfully cleared their infections. Descriptively, several of these low-frequency variants situated on disparate chromosomes displayed high inter-marker correlation coefficients exceeding 0.7. For example, the missense variant rs138078234 in RFTN1 correlated strongly with five other top-ranked variants, an intergenic marker on chromosome 4 was in perfect correlation with the AIRE missense variant rs34219046, and a 3-prime untranslated region variant in GRPEL1 correlated perfectly with an intergenic marker downstream of BNIP2 and GTF2A2. Because these rare variants co-occurred exclusively within the same small handful of individual genomes, the authors noted that such correlations represent descriptive co-carriage rather than evidence of genetic linkage or biological epistasis, cautioning against inferring molecular cooperation without formal carrier-exclusion testing.

In the genome-wide comparison evaluating overall susceptibility to acquiring infection, top-ranking markers included rs7024949 within intron 1 of LINGO2 on chromosome 9p21.1 and rs3087620 within exon 5 of EMP2 on chromosome 16, situated in close physical proximity to the DNA repair regulator TP53BP1. Rare-variant aggregation testing highlighted the Rho-GTPase regulator ARHGAP8 in susceptibility models and GYPC in persistent models. Exploratory Enrichr pathway queries applied to proximity-mapped genes surrounding the top five hundred markers generated diverse annotations, highlighting terms related to hospitalized COVID-19, inflammatory skin conditions, HIV-1 control, and the vaginal microbiome demethylmenaquinol-6 biosynthesis pathway, which encompassed loci such as DLG2 and LRP1B. The researchers explicitly noted that physical mapping within arbitrary physical windows does not establish biological causality or true linkage disequilibrium, designating all pathway enrichment results as purely hypothesis-generating observations requiring future functional validation.

To evaluate whether genomic findings translated into detectable local tissue alterations, the team quantified transcriptional expression for candidate genes identified around the lead chromosome 5 locus and from previously reported proteomic panels using quantitative polymerase chain reaction on cervical lysates. Among fourteen candidate targets initially screened, only assays for the non-coding RNA MIR378A and the translation factor EIF1 produced measurable amplification across three hundred and forty-eight clinical samples. Both MIR378A assay signals and EIF1 transcript levels were significantly elevated among women who were infected with human papillomavirus compared to double-negative control participants, with statistical significance ranging from p < 0.01 to p < 0.0001. However, neither biomarker demonstrated statistically significant differences between women who subsequently cleared their infections and those who developed persistent infections, indicating that the altered expression patterns reflected general viral exposure status rather than biological mechanisms specific to persistence.

Crucially, methodological considerations surrounding the tissue expression assays further constrained biological interpretation. The MIR378A measurement utilized the TaqMan Hs04273260_s1 gene-expression assay, which does not discriminate mature microRNA molecules from precursor forms or host genomic DNA. Because the cervical specimens had been archived in RIPA lysis buffer and reverse-transcribed directly without prior DNase digestion or reverse-transcriptase-negative controls, potential genomic DNA contamination could not be excluded, precluding the assay from serving as functional validation of the rs13158830 association. The investigators also highlighted broader study limitations, including the modest sample size of twenty-four persistent cases, the absence of comprehensive adjustment for unmeasured behavioral or clinical covariates in the primary Cochran–Mantel–Haenszel scan, and the exclusive enrollment of women living with HIV, which limits generalizability to HIV-negative populations. Consequently, the authors concluded that while rs13158830 represents an intriguing exploratory candidate locus, all genetic associations and pathway annotations require rigorous replication in larger, independent prospective cohorts.

Subject of Research: Host genetic susceptibility to human papillomavirus infection and persistence among women living with HIV in Rwanda

Article Title: Genome-wide association study of human papillomavirus infection and persistence in women living with HIV in Rwanda

Article References: Naluai, Å. T., Uwamungu, S., Andersson, M., Zewdie, B. N., Muvunyi, C. M., Bienvenu, E., Hasséus, B., & Giglio, D. (2026). Genome-wide association study of human papillomavirus infection and persistence in women living with HIV in Rwanda. Infectious Agents and Cancer, 21(1), Article 72. https://doi.org/10.1186/s13027-026-00815-x

Image Credits: AI Generated

DOI: 10.1186/s13027-026-00815-x

Keywords: human papillomavirus, HPV persistence, genome-wide association study, women living with HIV, Rwanda, rs13158830, PPARGC1B, MIR378A, EIF1, cervical cancer screening, Cochran-Mantel-Haenszel test, Firth logistic regression, viral clearance, host genetics, high-risk HPV genotypes, Kigali

News Source: Juliet Wilcox. (November 17, 2026). Rwandan Cohort Study Identifies Exploratory Genetic Locus Linked to HPV Persistence. Scienmag.

Tags: cervical cancer screeningCochran-Mantel-Haenszel testEIF1Firth logistic regressionGenome-wide association studyHigh-risk HPV genotypesHost geneticsHPV persistencehuman papillomavirusKigaliMIR378APPARGC1Brs13158830Rwandaviral clearancewomen living with HIV
Share12Tweet7Share2ShareShareShare1

Related Posts

Enzyme USP30 Suppresses Ferroptosis in Gastric Cancer by Stabilizing S100A4

Enzyme USP30 Suppresses Ferroptosis in Gastric Cancer by Stabilizing S100A4

November 17, 2026
Ivonescimab Extends Overall Survival in Advanced Squamous Non-Small Cell Lung Cancer

Ivonescimab Extends Overall Survival in Advanced Squamous Non-Small Cell Lung Cancer

November 17, 2026

Photon-Counting CT Improves Image Quality and Cuts Radiation Dose in Myeloma

November 17, 2026

Inhibiting Tumor Suppressor Lactylation Restores Antitumor Activity in Liver Cancer Review

November 17, 2026

POPULAR NEWS

  • Endometrial Receptivity During Embryo Implantation Linked to Endoplasmic Reticulum Stress

    Endometrial Receptivity During Embryo Implantation Linked to Endoplasmic Reticulum Stress

    29 shares
    Share 12 Tweet 7
  • Floral and Genetic Traits Differentiate Dwarf Succulent Species in South Africa

    29 shares
    Share 12 Tweet 7
  • Protocol Outlines Precise Chromosomal DNA Manipulations in Plants Using Programmable Recombinases

    29 shares
    Share 12 Tweet 7
  • Mild Respiratory Viruses Do Not Accelerate Biological Immune Aging After Recovery

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Irish Primary Care Fourteen-Day Helicobacter Pylori Treatments Rose Twenty-Eight Percent Annually

Madagascar Prison Inmates Accepted COVID-19 Vaccination as an Individual Health Choice

Small Molecules Activate Telomerase and Attenuate Senescence Stress in Human Fibroblasts

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.